StockTitan

@stocktitan.net

2 days ago

bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026 bioAffinity Technologies (Nasdaq: BIAF) reported that CyPath Lung unit sales in Q1 2026 rose 146% year-over-year on preliminary unaudited data, reflecting accelerating physician adoption. The company noted 2025 revenue +87% YoY and test units +99% vs 2024, targeting a $3.58B U.S. addressable market.Management highlighted clinical use in nodule management, a planned large longitudinal study, and R&D into asthma and COPD diagnostics to broaden the platform.

#BIAF #BIAFW bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026

www.stocktitan.net/news/BIAF/bio-affinity-t...

StockTitan

@stocktitan.net

2 weeks ago

New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures bioAffinity Technologies (Nasdaq: BIAF) published a clinical case study showing its noninvasive CyPath® Lung test informed care for a 71-year-old high-risk patient with multiple pulmonary nodules.The test returned an “Unlikely Malignancy” result; a three-month CT follow-up in October 2025 showed resolution of suspicious nodules and stability of another, avoiding invasive biopsy.Clinical study metrics: 92% sensitivity, 87% specificity, 88% accuracy for detecting lung cancer in nodules 20 mm.

#BIAF #BIAFW New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures

www.stocktitan.net/news/BIAF/new-case-study...

StockTitan

@stocktitan.net

3 weeks ago

bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung bioAffinity Technologies (Nasdaq: BIAF) reported 2025 results highlighting commercialization progress for its noninvasive lung cancer test, CyPath® Lung. CyPath testing revenue rose 87% YoY and unit volume increased 99% YoY, while consolidated revenue fell 34% after discontinuing unprofitable pathology services. The company raised $16.9M, ended 2025 with $6.5M cash, and enrolled the first patient in a planned 2,000-patient longitudinal trial in March 2026.

#BIAF #BIAFW bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung

www.stocktitan.net/news/BIAF/bio-affinity-t...

StockTitan

@stocktitan.net

3 weeks ago

bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic bioAffinity Technologies (Nasdaq: BIAF) initiated a 2,000-patient, large-scale longitudinal clinical study to evaluate its CyPath® Lung noninvasive flow cytometry test for detecting early-stage lung cancer in high-risk patients with 6mm–<30mm nodules.Up to 20 sites, including VA centers and major military hospitals, will enroll patients over ~18 months with follow-up to 24 months (NCT07168993). Prior data showed 92% sensitivity, 87% specificity and 88% accuracy in nodules <20mm. The investigational assay will be called FlowPath Lung during the trial.

#BIAF #BIAFW bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic

www.stocktitan.net/news/BIAF/bio-affinity-t...

StockTitan

@stocktitan.net

1 month ago

bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients bioAffinity Technologies (Nasdaq: BIAF) presented a scientific poster at the AAAAI 2026 annual meeting on March 1, 2026, reporting that its diagnostic platform can detect antibody drug receptors in sputum for dupilumab and benralizumab.The research advances development of noninvasive tests to help match asthma and COPD patients with biologic therapies and to monitor inflammatory changes over time using the company's flow cytometry platform with automated AI analysis.

#BIAF #BIAFW bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients

www.stocktitan.net/news/BIAF/bio-affinity-t...

StockTitan

@stocktitan.net

2 months ago

Cancer test lab keeps gold-standard accreditation after inspection College of American Pathologists renews bioAffinity’s lab oversight as its CyPath Lung test targets a lung cancer market projected at $10.4B by 2034.

#BIAF #BIAFW bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation

www.stocktitan.net/news/BIAF/bio-affinity-t...

StockTitan

@stocktitan.net

4 months ago

bioAffinity Technologies (Nasdaq: BIAF) to present CyPath Lung Stage 1A cases at ACS National Lung Cancer Roundtable bioAffinity’s noninvasive CyPath Lung sputum test will be spotlighted at the ACS National Lung Cancer Roundtable, with three Stage 1A cases guiding complex nodule workups.

#BIAF #BIAFW bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable

www.stocktitan.net/news/BIAF/bio-affinity-t...

StockTitan

@stocktitan.net

4 months ago

#BIAF #BIAFW bioAffinity Technologies Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/BIAF/bio-affinity-t...

StockTitan

@stocktitan.net

4 months ago

#BIAF #BIAFW bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume

www.stocktitan.net/news/BIAF/bio-affinity-t...

StockTitan

@stocktitan.net

5 months ago

bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases bioAffinity Technologies (Nasdaq: BIAF) announced that IP Australia has accepted Australian patent application AU 2019253111 for its platform to assess lung health and predict multiple lung diseases. The application covers methods using flow cytometry with fluorescent probes to detect cellular and molecular signatures in sputum samples. The acceptance adds to bioAffinity’s global estate—18 awarded and 33 pending patents—and complements the company’s flagship CyPath® Lung diagnostic. The patent will be automatically issued three months after acceptance unless a third party files an opposition before issuance.

#BIAF #BIAFW bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases

www.stocktitan.net/news/BIAF/bio-affinity-t...

StockTitan

@stocktitan.net

5 months ago

bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer bioAffinity Technologies (Nasdaq: BIAF) received a notification of allowance from the USPTO for a patent titled “Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning.”The allowed claim covers an AI-built algorithm and automated flow cytometry system that analyzes sputum cell populations and patient age to predict early-stage lung cancer and supports the company’s commercial CyPath® Lung test. The allowance expands bioAffinity’s global estate to 18 awarded and 33 pending patents across multiple jurisdictions.

#BIAF #BIAFW bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer

www.stocktitan.net/news/BIAF/bio-affinity-t...

StockTitan

@stocktitan.net

5 months ago

WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules bioAffinity Technologies (NASDAQ: BIAF, BIAFW) entered definitive agreements for a registered direct offering of 720,000 common shares at $2.50 per share, expected to close on or about October 9, 2025. Gross proceeds are expected to be approximately $1.8 million before placement agent fees and offering expenses. WallachBeth Capital is sole placement agent. The company intends to use net proceeds for working capital, to support expected growing sales of CyPath® Lung, and for general corporate purposes. The shares are offered under an effective Form S-3 shelf registration (File No. 333-275608) and a prospectus supplement will be filed with the SEC.

#BIAFW #BIAF WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

www.stocktitan.net/news/BIAFW/wallach-beth-...

StockTitan

@stocktitan.net

5 months ago

bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules bioAffinity Technologies, Inc., a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has entered into definitive agreements for the purchase and sale of 720,000 shares of common stock, par value $0.007 per share, at a purchase price of $2.50 per share in a registered direct offering...

#BIAF #BIAFW bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

www.stocktitan.net/news/BIAF/bio-affinity-t...

StockTitan

@stocktitan.net

5 months ago

bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025 bioAffinity Technologies (Nasdaq: BIAF) reported record CyPath® Lung test volumes in Q3 2025, with sales up 95% versus Q2 2025 and a 97% increase in sales for the first nine months of 2025 versus the same period in 2024. The company cited growing adoption by Veterans’ hospitals and expansion in the mid-Atlantic region.Management highlighted a 77% increase in new patients using CyPath® Lung in Q3 and improved at-home sample collection compliance. Published case studies cited earlier detection (including Stage 1A) and fewer unnecessary invasive procedures.

#BIAF #BIAFW bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025

www.stocktitan.net/news/BIAF/bio-affinity-t...

StockTitan

@stocktitan.net

6 months ago

Cancer Detection Biotech bioAffinity Technologies Raises $4.8M Through Public Offering of 1.9M Shares bioAffinity Technologies prices public offering of 1.92M shares at $2.50 per share, with pre-funded warrants at $2.493. WallachBeth Capital acts as sole placement agent. Closing expected Sept 30.

#BIAFW #BIAF WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m

www.stocktitan.net/news/BIAFW/wallach-beth-...

StockTitan

@stocktitan.net

6 months ago

Cancer Detection Biotech bioAffinity Technologies Raises $4.8M Through Public Share Offering at $2.50 Cancer detection biotech bioAffinity Technologies announces $4.8M public offering of 1.92M shares at $2.50 each, with pre-funded warrants at $2.493. Closing expected September 30, 2025.

#BIAF #BIAFW bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering

www.stocktitan.net/news/BIAF/bio-affinity-t...

StockTitan

@stocktitan.net

6 months ago

Early-Stage Lung Cancer Detection: bioAffinity's CyPath Test Proves Value in Critical Patient Cases Noninvasive CyPath Lung diagnostic helps detect Stage 1A lung cancer and guides treatment decisions in 3 new case studies. Test aids physician decision-making for suspicious nodules.

#BIAF #BIAFW bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung

www.stocktitan.net/news/BIAF/bio-affinity-t...

StockTitan

@stocktitan.net

6 months ago

1-for-30 Reverse Split: bioAffinity Technologies Restructures Shares to Maintain Nasdaq Listing Biotech company bioAffinity Technologies implements 1:30 reverse stock split effective Sept 19, reducing outstanding shares to 1.3M. Move aims to meet Nasdaq minimum bid requirements.

#BIAF #BIAFW bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025

www.stocktitan.net/news/BIAF/bio-affinity-t...

StockTitan

@stocktitan.net

6 months ago

Ground-Breaking Lung Test Cuts 5-Year Wait to Immediate Cancer Diagnosis: bioAffinity's CyPath Success bioAffinity's CyPath Lung diagnostic successfully identified lung cancer in 13mm ground-glass nodules, reducing diagnosis time from 5-year monitoring to immediate treatment in high-risk patient.

#BIAF #BIAFW Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules

www.stocktitan.net/news/BIAF/case-study-cy-...

StockTitan

@stocktitan.net

7 months ago

U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA U.S. Medicine, a leading publication for federal healthcare professionals, has featured bioAffinity Technologies’ CyPath ® Lung in its pulmonary issue, highlighting the test’ s potential to improve lung cancer detection while lowering costs for the Department of Veterans Affairs. “We are honored that U.S. Medicine recognized both the economic and clinical...

#BIAF #BIAFW U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA

www.stocktitan.net/news/BIAF/u-s-medicine-m...

StockTitan

@stocktitan.net

7 months ago

Early-Stage Lung Cancer Test Shows Strong Growth as bioAffinity Raises Prices, Expands Distribution bioAffinity's CyPath Lung test detected Stage 1A cancers missed by other tests. Company secured $3.25M funding and Cardinal Health partnership to scale operations. Learn more.

#BIAF #BIAFW bioAffinity Technologies Reports Second Quarter 2025 Results

www.stocktitan.net/news/BIAF/bio-affinity-t...

StockTitan

@stocktitan.net

7 months ago

Early Cancer Detection Biotech Secures $1.2M Funding to Advance Noninvasive Testing Technology bioAffinity Technologies arranges private placement of preferred stock and warrant restructuring to strengthen its early-stage cancer detection programs. Learn deal specifics.

#BIAF #BIAFW bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

www.stocktitan.net/news/BIAF/bio-affinity-t...

StockTitan

@stocktitan.net

7 months ago

bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales bioAffinity Technologies (NASDAQ: BIAF) reported significant growth in sales of its CyPath® Lung cancer diagnostic test. July test volume showed a 72% increase over the previous monthly average for H1 2025, marking consecutive record-breaking months in June and July.The company reaffirmed its forecast of 3X year-over-year revenue growth for CyPath® Lung. The growth is attributed to increasing physician adoption and successful case studies showing the test's ability to detect Stage 1A lung cancer in cases where standard imaging and other tests indicated benign conditions.bioAffinity is expanding beyond its successful Texas pilot program into the Mid-Atlantic region and Veterans Administration healthcare system. The company's Texas program, reaching approximately 6% of U.S. pulmonologists, has validated their marketing approach.

#BIAF #BIAFW bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales

www.stocktitan.net/news/BIAF/bio-affinity-t...

StockTitan

@stocktitan.net

8 months ago

Revolutionary CyPath Lung Test Catches Hidden Cancer After Standard Tests Failed: Critical Case Study Reveals Non-invasive sputum test identifies rare lung cancer missed by PET scan and blood tests, enabling life-saving early intervention. See breakthrough results.

#BIAF #BIAFW Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results

www.stocktitan.net/news/BIAF/case-study-cy-...

StockTitan

@stocktitan.net

8 months ago

Breakthrough: New Lung Cancer Test Catches Hidden Stage 1A Tumor Other Diagnostics Missed CyPath Lung successfully identified a 13mm neuroendocrine tumor after multiple conventional tests failed to detect cancer. See clinical validation details.

#BIAF #BIAFW Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools

www.stocktitan.net/news/BIAF/case-study-cy-...

StockTitan

@stocktitan.net

8 months ago

Revolutionary Lung Cancer Test Gets Canadian Patent: 92% Accuracy in Early Detection Where Cancer Deaths Lead New patent protects breakthrough lung cancer diagnostic test showing 92% sensitivity in early detection. Expands to Canadian market where 31,000 diagnoses occur annually. Learn more.

#BIAF #BIAFW Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic

www.stocktitan.net/news/BIAF/canada-awards-...

StockTitan

@stocktitan.net

8 months ago

bioAffinity's Revolutionary Lung Cancer Test Gets China Patent: Targets 300M Smokers With 92% Accuracy New patent enables early lung cancer detection in China's 300M smokers. Test shows 92% sensitivity in clinical trials. See how this breakthrough impacts global expansion.

#BIAF #BIAFW bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic

www.stocktitan.net/news/BIAF/bio-affinity-t...

StockTitan

@stocktitan.net

8 months ago

Revolutionary Lung Cancer Test Succeeds Where PET Scans Failed: Stage 1A Detection Breakthrough New case study reveals how CyPath Lung test detected early-stage cancer in high-risk patient when traditional diagnostics proved inconclusive. See clinical results.

#BIAF #BIAFW Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging

www.stocktitan.net/news/BIAF/case-study-cy-...

StockTitan

@stocktitan.net

9 months ago

Revolutionary Cancer Treatment Breakthrough: New RNA Therapy Shows Selective Kill Rate Across 5 Cancer Types New data reveals dual-target RNA therapy selectively eliminates cancer cells while sparing healthy tissue. Effective across lung, breast, brain cancers. See breakthrough results.

#BIAF #BIAFW bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

www.stocktitan.net/news/BIAF/bio-affinity-t...

StockTitan

@stocktitan.net

9 months ago

Revolutionary siRNA Cancer Therapy Targets Skin Cancer: bioAffinity Secures Key China Patent Novel siRNA therapy selectively kills cancer cells by targeting dual receptors. bioAffinity advances topical skin cancer treatment development. See breakthrough details.

#BIAF #BIAFW bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy

www.stocktitan.net/news/BIAF/bio-affinity-t...